Recognizing and diagnosing heart failure in patients with HCM
Aleš Linhart, MD, PhD
Staging therapy in hypertrophic cardiomyopathy patients with heart failure: New insights
Pablo Garcia-Pavia, MD, PhD
Michelle Michels, MD
Evidence-based novel therapies in HCM
Optimal pharmacological management of HCM by clinical manifestations
Patient-clinician communication about obesity management
Martha Gulati, MD
The weight of cardiovascular risk: Addressing obesity in cardiac patients
Naveed Sattar, MD, PhD
John Deanfield, MD
Obesity: A looming cardiovascular threat – Pathophysiology, diagnosis and impact
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
Christie M. Ballantyne, MD, FACP, FACC
ACC 2024: The PIONEER AF-PCI Trial
Manesh R. Patel, MD
Emerging perspectives in the diagnosis and management of hypertrophic cardiomyopathy
Perry Elliott, MD
Iacopo Olivotto, MD
HCM: Understanding the condition
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Pam R. Taub, MD, FACC, FASPC
PCSK9i: Benefits across the spectrum of cardiovascular disease
Fabrice Martens, MD, PhD, FESC
The evolving need and challenges to reach LDL-c targets in high-risk patients
Prof. Kausik Ray, MBChB, MD, MPhil
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Exploring the role of a novel CETP inhibitor in lipid management
Roxana Mehran, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.